De­spite the rise of a vac­cine skep­tic in the cam­paign of US pres­i­den­tial elec­tion win­ner Don­ald Trump, GSK CEO Em­ma Walm­s­ley be­lieves her com­pa­ny can … ...

Emma Walmsley, CEO of GSK leading the keynote at the FT Live Global Pharma and Biotech Summit in London. Credit: Jenna Philpott / GlobalData. Following Donald Trump’s re-election as the 47 th ...

With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

Net Debt: GBP13 billion, a reduction of GBP2 billion compared to December 2023. Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth ...

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales. The company ...

Learn More. GSK (LSE: GSK) shares fell 3.4% to 1,401p today (30 October) after the drugmaker released a trading update covering the third quarter (Q3). This means the FTSE 100 stock is down 16% in ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...